Tardive Dyskinesia
8
Pipeline Programs
4
Companies
4
Clinical Trials
4
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
1
1
5
Early DiscoveryClinical DevelopmentMarket
On Market (4)
Approved therapies currently available
UP
UP
U
LEVETIRACETAMApproved
levetiracetam
Unknown Companyoral2012
U
SPRITAMApproved
levetiracetam
Unknown Companyoral2015
Competitive Landscape
3 companies ranked by most advanced pipeline stage
TevaIsrael - Petach Tikva
2 programs1
1
Deutetrabenazine Oral CapsulePhase 41 trial
SD-809Phase 2/31 trial
Active Trials
UP
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
TevaDeutetrabenazine Oral Capsule
TevaSD-809
MedicurePyridoxal 5'-Phosphate
Clinical Trials (4)
Total enrollment: 192 patients across 4 trials
Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
Start: Mar 2026Est. completion: Oct 202725 patients
Phase 4Not Yet Recruiting
Phase 3Completed
Aim to Reduce Movements in Tardive Dyskinesia
Start: Jun 2014Est. completion: May 2015117 patients
Phase 2/3Completed
Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia
Start: May 2009Est. completion: Aug 2014
Phase 2Terminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
4 companies competing in this space